GlassScriptPhysician profile
Michael L Salter
NPI 1376833905
$18,705.54
in general payments reported to CMS, 2019-2025
29 companies · $2,346 in 2025
The $2,346 reported for 2025 was more than what 83% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,404 · 2020: $2,646 · 2021: $4,957 · 2022: $1,965 · 2023: $3,151 · 2024: $2,235 · 2025: $2,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,401 · Long Term Medical Supply Or Device Loan: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,401.24 |
| Long Term Medical Supply Or Device Loan | $1,331.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,892.34 | 2019-2022 | |
| Alcon Vision LLC | $3,948.47 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Abbvie INC. | $1,977.06 | 2022-2025 | Xen Glaucoma Treatment System, Durysta, Alphagan P |
| Carl Zeiss Meditec USA, INC. | $1,331.45 | 2023 | Artevo 800 |
| Glaukos Corporation | $951.34 | 2019-2025 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Iaccess Precision Blade, Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $460.82 | 2019-2021 | |
| New World Medical,INC. | $452.37 | 2020-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Sight Sciences, INC. | $428.60 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ivantis, INC | $410.40 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $212.33 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $207.50 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $201.88 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $162.64 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $157.43 | 2020-2025 | Cequa |
| Alexion Pharmaceuticals, INC. | $152.38 | 2024 | Ultomiris |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $151.17 | 2019-2023 | |
| Thea Pharma INC. | $95.86 | 2023-2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $80.89 | 2022-2023 | Tyrvaya |
| Rxsight INC | $68.56 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Mallinckrodt Hospital Products INC. | $64.71 | 2025 | Acthar |
| Ocular Therapeutix, INC. | $56.66 | 2022-2024 | Dextenza |
| Akorn Operating Company LLC | $52.31 | 2021 | |
| Eyepoint US, INC. | $45.26 | 2019-2021 | |
| Iridex Corporation | $39.83 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $24.56 | 2021 | |
| Nova Eye, INC. | $24.47 | 2024 | |
| Akorn, INC. | $23.56 | 2020 | |
| Eyevance Pharmaceuticals LLC | $17.10 | 2019 | |
| Horizon Therapeutics Plc | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Salter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.